They also found that the regional delivery of HER2 CAR T provided improved tumor response as compared to systemic delivery, while limiting toxicity that may come with CAR T therapy, such as multiple organ dysfunction secondary to cytokine storm, through their specific engineered costimulatory domain [57, 58]. This evidence concerns the gene ERBB2 and neoplasm.